Kevin Feeley Sells 275 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 275 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $21,582.00. Following the completion of the transaction, the chief financial officer now directly owns 2,950 shares in the company, valued at $231,516. This trade represents a 8.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total value of $886,521.44.

GeneDx Stock Down 3.9 %

Shares of NASDAQ:WGS traded down $3.01 on Friday, hitting $74.85. 393,012 shares of the company traded hands, compared to its average volume of 865,986. GeneDx Holdings Corp. has a 52 week low of $3.62 and a 52 week high of $98.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a 50 day simple moving average of $78.37 and a 200-day simple moving average of $57.69. The company has a market cap of $2.06 billion, a PE ratio of -24.07 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period last year, the company earned ($0.82) earnings per share. The company’s revenue was up 44.3% on a year-over-year basis. As a group, research analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

WGS has been the topic of several analyst reports. Craig Hallum upped their price target on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group upped their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. TD Cowen upped their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company upped their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average target price of $70.67.

Institutional Investors Weigh In On GeneDx

Several large investors have recently bought and sold shares of the business. Global Retirement Partners LLC purchased a new position in GeneDx in the fourth quarter worth about $28,000. New York State Common Retirement Fund raised its stake in GeneDx by 347.0% during the 4th quarter. New York State Common Retirement Fund now owns 68,072 shares of the company’s stock valued at $5,232,000 after purchasing an additional 52,843 shares during the period. Principal Financial Group Inc. raised its stake in GeneDx by 10.6% during the 4th quarter. Principal Financial Group Inc. now owns 15,751 shares of the company’s stock valued at $1,211,000 after purchasing an additional 1,511 shares during the period. Palumbo Wealth Management LLC raised its stake in GeneDx by 22.8% during the 4th quarter. Palumbo Wealth Management LLC now owns 8,303 shares of the company’s stock valued at $638,000 after purchasing an additional 1,542 shares during the period. Finally, Rhumbline Advisers raised its stake in GeneDx by 5.5% during the 4th quarter. Rhumbline Advisers now owns 19,750 shares of the company’s stock valued at $1,518,000 after purchasing an additional 1,021 shares during the period. 61.72% of the stock is currently owned by institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.